Tennessee Senate Bill SB2437

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 47; Title 53; Title 56; Title 63 and Title 68, relative to medications approved by the federal food and drug administration.

Summary

Senate Bill 2437 aims to amend certain sections of the Tennessee Code Annotated concerning medications that have been approved by the Federal Food and Drug Administration (FDA). The bill primarily focuses on providing clearer guidelines regarding the handling and regulation of these medications, particularly emphasizing the responsibilities of the owners or persons in legal possession of the drugs. By establishing a more formalized process requiring the owners to request hearings within a specified time frame, the bill seeks to enhance accountability and compliance within the pharmaceutical landscape in Tennessee. The legislation modifies existing regulations under several titles, namely Title 47, Title 53, Title 56, Title 63, and Title 68, thereby addressing a range of issues relating to both the approval and management of medications. One notable aspect of the bill is its intent to streamline the process by which individuals or entities can contest the categorization of their medications, necessitating a formal request for hearings upon receipt of specific notices. This is seen as a step towards improving the regulatory framework that governs the pharmaceutical sector in the state. Moreover, proponents of the bill argue that this enhanced process will lead to better oversight and, ultimately, greater public health safety. By putting in place a more structured approach to disputing drug classifications, the bill aims to safeguard consumer welfare through clearer pathways for addressing disputes. The increased communication between the governing board and medication owners is expected to foster a more transparent environment. On the other hand, potential concerns have been raised regarding the implications for individuals or smaller entities who may struggle to navigate the legal requirements imposed by the bill. Critics fear that the timeline for requests could disadvantage those who may not have immediate access to legal representation or the necessary knowledge about the regulatory processes. This conflict may complicate efforts to ensure that both public health needs and the rights of individuals are adequately protected under the law.